Schroder, F.H.

cancer prostate prostate cancer study screening biopsy mortality level signi group ficant patient incidence erspc result diagnosis prostate volume volume treatment disease trial european igf-i number death prostate cancer risk factor effect antigen population urology prostatic rp group european randomized study value netherland difference outcome psa level rotterdam detection randomized analysis gleason prevention survival control prostatic hyperplasia prostate cancer incidence erectile dysfunction score prostate-speci fic antigen igfbp follow-up dysfunction round table interval screening round reduction growth family history schroder erectile evidence baseline serum stage mortality rates increase prostate cancers disease-speci fic mortality prostate cancer screening tumor control arm roobol igfbp -3 levels period schroder fh progression